{"nctId":"NCT00343889","briefTitle":"Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine","startDateStruct":{"date":"2006-08"},"conditions":["Diphtheria","Tetanus","Pertussis","Hepatitis B","Haemophilus Infections"],"count":379,"armGroups":[{"label":"Group 1: DTaP-Hep B-PRP-T + Oral Polio Vaccine (OPV) vaccine","type":"EXPERIMENTAL","interventionNames":["Biological: DTaP-HB-PRP~T vaccine + OPV","Biological: Oral Polio Vaccine"]},{"label":"Group 2: Tritanrix-HepB/Hib™ + OPV vaccine","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Tritanrix-HepB/Hib™ + OPV vaccine","Biological: Oral Polio Vaccine"]}],"interventions":[{"name":"DTaP-HB-PRP~T vaccine + OPV","otherNames":[]},{"name":"Tritanrix-HepB/Hib™ + OPV vaccine","otherNames":[]},{"name":"Oral Polio Vaccine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Six week old infants (42 to 50 days old) on the day of inclusion; of either gender.\n* Mother tested as seronegative for hepatitis B surface antigen (HBsAg) between 28 weeks of pregnancy and up to 4 days after delivery\n* Born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg\n* Informed consent form signed by one parent or other legal representative if appropriate (independent witness is mandatory if parent is illiterate)\n* Able to attend all scheduled visits and to comply with all trial procedures.\n\nExclusion Criteria:\n\n* Participation in another clinical trial in the 4 weeks preceding the first trial vaccination\n* Planned participation in another clinical trial during the present trial period\n* Congenital or acquired immunodeficiency; immunosuppressive therapy such as long-term systemic corticosteroid therapy.\n* Chronic illness at a stage that could interfere with the conduct or completion of the trial\n* Blood or blood-derived products received since birth\n* HB vaccination since birth\n* Any vaccination in the four weeks preceding the first trial vaccination\n* Any planned vaccination (except trial vaccines and bacillus Calmette-Guerin (BCG) during the trial\n* Documented history of pertussis, tetanus (T), diphtheria (D), polio, or Haemophilus influenzae type b (Hib) infection(s) (confirmed either clinically, serologically, or microbiologically)\n* Known personal or maternal history of HIV, HBsAg or hepatitis C seropositivity\n* Thrombocytopenia or a bleeding disorder contraindicating intramuscular (IM) vaccination\n* History of seizures\n* Febrile (rectal temperature ≥ 38.0°C) or acute illness on the day of inclusion.","healthyVolunteers":true,"sex":"ALL","minimumAge":"42 Days","maximumAge":"50 Days","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Number of Participants With Anti-Hepatitis B Responses After Vaccination With Either DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) or Tritanrix-Hep B/Hib™ Concomitantly With OPV","description":"Immunogenicity was assessed by means of radioimmunoassay (RIA) for hepatitis B (HBs) antibodies.\n\nAnti-Hepatitis B Responses was defined as titers ≥ 100 mIU/mL at 30 days after the third vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Seroprotection to Hepatitis H Antigen After Vaccination With Either DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) or Tritanrix-Hep B/Hib™ Concomitantly With OPV","description":"Immunogenicity was assessed by means of radioimmunoassay (RIA) for hepatitis B (HBs) antibodies.\n\nSeroprotection was defined as titers ≥ 10 mIU/mL at 30 days after the third vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"167","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers (GMTs) of Vaccine Antibodies After Vaccination With Either DTaP-Hep B-PRP-T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV","description":"Immunogenicity were assessed by means of enzyme immunoassay (EIA) for antibodies to the vaccine antigens 1 month after the third vaccination (Day 150).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.1","spread":null},{"groupId":"OG001","value":"86.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.35","spread":null},{"groupId":"OG001","value":"7.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.018","spread":null},{"groupId":"OG001","value":"0.018","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.30","spread":null},{"groupId":"OG001","value":"1.76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.16","spread":null},{"groupId":"OG001","value":"5.84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.50","spread":null},{"groupId":"OG001","value":"5.71","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Anti-Diphtheria and Anti-Tetanus Responses After Vaccination With Either DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) or Tritanrix-Hep B/Hib™ Concomitantly With OPV","description":"Immunogenicity was assessed by means of radioimmunoassay (RIA) for Diphtheria and Tetanus antibodies.\n\nAnti-Diphtheria and anti-tetanus Responses were assayed at ≥ 0.01 IU/mL and at ≥ 0.1 IU/mL at 30 days after the third vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"137","spread":null},{"groupId":"OG001","value":"134","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"184","spread":null},{"groupId":"OG001","value":"186","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"184","spread":null},{"groupId":"OG001","value":"186","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Seroconversion for Anti-Pertussis and Anti-Filamentous Hemagglutinin Antibodies After Vaccination With Either DTaP-Hep B-PRP-T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV","description":"Anti-Pertussis toxoid and Anti-Filamentous Hemagglutinin antibodies were assessed by means of enzyme immunoassay (EIA).\n\nSeroconversion was defined as ≥ 4 fold increase in antibody titers from Day 0 to 30 days after the third vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"183","spread":null},{"groupId":"OG001","value":"168","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"178","spread":null},{"groupId":"OG001","value":"116","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting At Least One Solicited Injection Site and Systemic Reaction Following Each Vaccination With Either DTaP-Hep B-PRP-T Concomitantly With Oral Polio Vaccine (OPV) or Tritanrix-Hep B/Hib™ Concomitantly With OPV","description":"Solicited injection site reactions: Tenderness, Erythema, and Swelling; Systemic reactions: Fever (Temperature), Vomiting, Crying, Somnolence, Anorexia, and Irritability.\n\nGrade 3 reactions defined as: Tenderness - cries when injected limb is moved; Erythema and Swelling - ≥ 5cm; Fever - temperature ≥ 39.6ºC; Vomiting - ≥6 episodes per 24 hours; Crying - inconsolable crying for \\>3 hours; Somnolence - sleeping most of the time or difficulty to wake up; Anorexia - refuses ≥3 feeds; and Irritability - inconsolable.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null},{"groupId":"OG001","value":"152","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"142","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"109","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"148","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"107","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"129","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"106","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"128","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"116","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":190},"commonTop":["Injection site pain","Injection site erythemia","Irritability","Pyrexia","Upper respiratory tract infection"]}}}